Sci Transl Med
Dr. Pedram Razavi, MD, PhD
- Medicare services, 2024
- 155
- Medicare patients, 2024
- 55
- Part D claims, 2024
- 58
- Publications
- 114
- MIPS score, 2024
- 78
- Practice address
- 1275 York Avenue, New York, NY 10065
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Razavi's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Pedram Razavi is a medical oncologist in New York, New York
Dr. Razavi practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
Dr. Razavi's NPI, 1841562113, was assigned on February 2, 2012. Dr. Razavi graduated from Tehran University of Medical Sciences School of Medicine in 2001. Dr. Razavi holds New York license 270779.
- NPI
- 1841562113NPI Registry (opens in a new tab)
- Medicare PAC ID
- 3274881875
- NPI enumeration date
- February 2, 2012
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 51
- Medical school graduation
- 2001
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Pedram Razavi practices at Memorial Sloan Kettering Cancer Center in New York, New York
Dr. Razavi's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.
- Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10065
Source: Dmand AI Affiliation Data
Dr. Pedram Razavi is affiliated with 2 sites of care and 4 medical groups
Dr. Razavi's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Razavi to 3 more medical groups and 1 home health agency, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Pedram Razavi's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razavi practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Memorial Sloan Kettering Cancer Center | Available with a free account |
| +1 more site and 3 medical groups | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Pedram Razavi is one of 458 medical oncologists in New York
Medical oncology is Dr. Razavi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Razavi is licensed in New York.
Specialties and state licenses
- Medical oncology, New YorkPrimary
Clinical focus
Dmand AI lists breast cancer among the conditions Dr. Razavi treats.
Medical oncologists near Dr. Razavi
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Pedram Razavi billed Medicare for 155 services in 2024
CMS data shows 155 Medicare services from Dr. Razavi across 4 procedure codes in 2024, for 55 Medicare patients. Medicare paid $15,622 for them.
Dr. Razavi's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 1182024: 13414%
- Other services
- 2023: 02024: 21
Where Dr. Razavi's Medicare services took place, 2024
- In an office12681%
- In a facility2919%
Dr. Razavi compared with the New York median for medical oncologists, 2024
- Dr. Razavi
- New York median
- Medicare services
- 155vs 34054% below
- Medicare patients
- 55vs 11251% below
- Part D claims
- 47vs 13064% below
Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.
Dr. Razavi's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Razavi?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Razavi and other medical oncologists in New York.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Pedram Razavi treated 55 Medicare patients in 2024, average age 72
CMS counts 55 Medicare patients who saw Dr. Razavi in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have cancer, and 62% have high blood pressure. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Razavi's median patient age at 69, with 95% women.
Dr. Razavi's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Chronic conditions among Dr. Razavi's Medicare patients, 2024
- Cancer75%
- High blood pressure62%
- High cholesterol60%
- Anxiety55%
- Arthritis55%
- Osteoporosis38%
- Mood disorders35%
- Diabetes29%
Share of Medicare patients with each condition. A patient can have several.
Dr. Razavi's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 69
Patient panel by sex, all payers
- Women95%
- Men2%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Pedram Razavi wrote 58 Medicare Part D claims in 2024
In 2024, Dr. Razavi wrote 58 Medicare Part D claims for 22 patients. 66% of them were for generic drugs. CMS names the drug for 47 of them, across 2 drugs with 11 or more claims each, at $1,897 in total drug cost. In 2022, CMS named 100 claims across 4 drugs.
Dr. Razavi's Part D claims by kind of drug, 2024
- Generic38 claims66%
- Brand-name20 claims34%
Dr. Razavi's most prescribed drugs by claims, 2023
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2022 to 2023
- 2022
- 2023
- Claims for drugs CMS names
- 2022: 1002023: 4753%
Drugs named by CMS: 2 in 2023, 4 in 2022.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Pedram Razavi scored 78 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Razavi for performance year 2024, reported as part of a group. Dr. Razavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Razavi as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Razavi's MIPS scores, performance year 2024
- 78of 100Final score
- 78.7of 100Quality
- 40of 100Improvement Activities
- 49of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Pedram Razavi has 114 publications on record
Dmand AI links 114 papers to Dr. Razavi, published from 2011 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Breast Neoplasms, Biomarkers, Tumor and Genomics. Dr. Razavi has published most often in Cancer Discov. Dr. Razavi's most frequent co-authors are Sarat Chandarlapaty, MD, PhD, Bob T. Li, MBBS, MPH and Mark E. Robson, MD.
Dr. Razavi's papers by year, 2016 to 2025
Topics Dr. Razavi writes about most
- Breast Neoplasms
- Biomarkers, Tumor
- Genomics
- Cell Line, Tumor
- Circulating Tumor DNA
- Drug Resistance, Neoplasm
- High-Throughput Nucleotide Sequencing
- Gene Expression Regulation, Neoplastic
Dr. Razavi's most frequent co-authors
- Sarat Chandarlapaty, MD, PhD38 shared papers
- Bob T. Li, MBBS, MPH22 shared papers
- Mark E. Robson, MD17 shared papers
Recent publications by Dr. Razavi
Circ Genom Precis Med
See who Dr. Razavi researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Razavi works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Pedram Razavi received $55,669 in industry payments from 2018 to 2025
CMS Open Payments shows 58 general payments to Dr. Razavi from 9 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 89% of the total. Novartis Pharmaceuticals Corporation paid the most, $21,197. It also lists 8 research payments totaling $15,639 from 2021 to 2025.
General payments to Dr. Razavi by program year, 2018 to 2025
General payments to Dr. Razavi by kind, 2018 to 2025
- Consulting fees$49,74189%
- Food and beverage$2,1244%
- Honoraria$2,0004%
- Travel and lodging$1,8043%
Companies that paid Dr. Razavi the most, 2018 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Pedram Razavi graduated from Tehran University of Medical Sciences School of Medicine
Dr. Razavi graduated from Tehran University of Medical Sciences School of Medicine in 2001.
- Medical school
Source: Dmand AI Professional Profile Data
Dr. Pedram Razavi accepts plans from 13 insurance carriers
Dr. Razavi is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.
- Aetna
- Excellus BlueCross BlueShield
- Blue Cross Blue Shield of Michigan
- United Healthcare
- Blue Cross Blue Shield of Massachusetts
- Elevance
- HCSC
- MVP Health Care
- +5 more carriersWith a free account
Plan types Dr. Razavi accepts, by number of carriers
- PPO9
- Medicare8
- EPO5
- POS5
- HMO4
- Medicaid1
Source: Dmand AI Insurance Network Data
Sources for Dr. Pedram Razavi's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Pedram Razavi
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Pedram Razavi's NPI number?
Dr. Pedram Razavi's NPI number is 1841562113. It was assigned on February 2, 2012, and it is active in the NPI Registry.
What kind of doctor is Dr. Pedram Razavi?
Dr. Pedram Razavi is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Pedram Razavi practice?
Dr. Razavi practices at 1275 York Avenue, New York, NY 10065. Dr. Razavi's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Razavi to 3 medical groups and 1 home health agency.
What is Dr. Pedram Razavi's medical license number?
Dr. Razavi holds New York license 270779.
Which hospitals is Dr. Pedram Razavi affiliated with?
Dr. Razavi practices at Memorial Sloan Kettering Cancer Center in New York, New York.
What medical group is Dr. Pedram Razavi part of?
Dr. Razavi is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Razavi to 3 more medical groups.
Does Dr. Pedram Razavi accept Medicare?
Yes. CMS data shows Dr. Razavi billed Medicare for 155 services in 2024, and Dr. Razavi accepts Medicare assignment.
Does Dr. Pedram Razavi offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Razavi as offering telehealth services.
What is Dr. Pedram Razavi's MIPS score?
Dr. Razavi's MIPS final score for performance year 2024 is 78 out of 100, reported as part of a group.
How many Medicare patients does Dr. Pedram Razavi see?
CMS counts 55 Medicare patients who saw Dr. Razavi in 2024, with an average age of 72.
Show 8 more questionsShow fewer questions
What services does Dr. Pedram Razavi bill to Medicare?
In 2024, Dr. Razavi's most billed Medicare services were office visit, established patient (99215), office visit, established patient (99214) and hospital inpatient care (99233).
Where did Dr. Pedram Razavi go to medical school?
Dr. Razavi graduated from Tehran University of Medical Sciences School of Medicine in 2001.
What drugs does Dr. Pedram Razavi prescribe most?
In 2023 Medicare Part D data, Dr. Razavi's most prescribed drugs by claims were Letrozole and Anastrozole.
Has Dr. Pedram Razavi received payments from drug or device companies?
CMS Open Payments shows $55,669 in general payments to Dr. Razavi from 9 companies from 2018 to 2025. The largest total came from Novartis Pharmaceuticals Corporation.
How long has Dr. Pedram Razavi been practicing?
Dr. Razavi graduated from medical school in 2001, 25 years ago.
Does Dr. Pedram Razavi do research?
Dmand AI links 114 publications to Dr. Razavi, published from 2011 to 2025.
Who does Dr. Pedram Razavi publish with?
Dr. Razavi's most frequent co-authors are Sarat Chandarlapaty, MD, PhD (38 shared papers), Bob T. Li, MBBS, MPH (22 shared papers) and Mark E. Robson, MD (17 shared papers).
What insurance does Dr. Pedram Razavi accept?
Dr. Razavi is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in New York by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card